SCHEMBL727965

SCHEMBL727965

Cc1nc(-c2ccc(OCCCCCOc3ccc(C(=N)N)cc3)cc2)c(C(C)C)s1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRMT1 Q99873 3/20 0.53
PLAU P00749 3/20 0.53
PLG P00747 3/20 0.53
F2 P00734 2/20 0.53
ST14 Q9Y5Y6 2/20 0.53
TMPRSS2 O15393 2/20 0.53
PRMT5 O14744 1/20 0.53
SLC22A2 O15244 1/20 0.53
SLC22A1 O15245 1/20 0.53
PTP4A3 O75365 1/20 0.53
SLC22A3 O75751 1/20 0.53
F10 P00742 1/20 0.53
S100B P04271 1/20 0.53
CHRM2 P08172 1/20 0.53
CHRM4 P08173 1/20 0.53
CHRM5 P08912 1/20 0.53
ADRA2A P08913 1/20 0.53
CYP2D6 P10635 1/20 0.53
AOC1 P19801 1/20 0.53
MAOA P21397 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL3241146 0.99 PRSS1 (0.54) PRMT1PLAUPLGF2ST14
SCHEMBL3192337 0.99 PRSS1 (0.52) PRMT1PLAUPLGF2ST14
SCHEMBL11936601 0.89 MEN1 (0.38) PRMT1PLAUPLGF2ST14
SCHEMBL27832557 0.88 PRSS1 (0.49) PRMT1PLAUPLGF2ST14
SCHEMBL12213745 0.87 GAA (0.53) PRMT1PLAUPLGF2ST14
SCHEMBL729742 0.87 MEN1 (0.37) PRMT1PLAUPLGF2ST14
SCHEMBL13686121 0.87 GAA (0.53) PRMT1PLAUPLGF2ST14
SCHEMBL3666899 0.87 GAA (0.53) PRMT1PLAUPLGF2ST14
SCHEMBL727316 0.87 MEN1 (0.37) PRMT1PLAUPLGF2ST14
SCHEMBL729017 0.86 PRMT1 (0.58) PRMT1PLAUPLGF2ST14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8227496-B2 Use of 4-[(4-thiazolyl)phenoxy]alkoxy-benzamidine derivatives for treatment of osteoporosis DONG WHA PHARMACEUTICAL CO., LTD (KR) 2012-07-24 US claimed
JP-2011529875-A 2011-12-15 JP claimed
US-7964584-B2 Method of treating or preventing osteoporosis comprising administering to a patient in need thereof an effective amount of pharmaceutical composition comprising benzamidine derivatives or their salts, and alendronic acid or its salt DONG WHA PHARMACEUTICAL CO., LTD. (KR) 2011-06-21 US claimed
EP-2307015-A2 A PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING OSTEOPOROSIS COMPRISING BENZAMIDINE DERIVATIVES OR THEIR SALTS, AND ALENDRONIC ACID OR ITS SALT Dong Wha Pharmaceutical Co., Ltd. (KR) 2011-04-13 EP claimed
EP-1411935-B1 USE OF 4- (4-THIAZOLYL)PHENOXL ALKOXY-BENZAMIDINE DERIVATIVES FOR TREATMENT OF OSTEOPOROSIS DONG WHA PHARM CO LTD (KR) 2010-05-19 EP claimed
US-20100120875-A1 USE OF 4-[(4-THIAZOLYL)PHENOXY]ALKOXY-BENZAMIDINE DERIVATIVES FOR TREATMENT OF OSTEOPOROSIS DONGWHA PHARMACEUTICAL CO., LTD. 2010-05-13 US claimed
WO-2010013969-A2 A PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING OSTEOPOROSIS COMPRISING BENZAMIDINE DERIVATIVES OR THEIR SALTS, AND ALENDRONIC ACID OR ITS SALT DONG WHA PHARMACEUTICAL CO., LTD. (KR) 2010-02-04 WO claimed
US-20100029595-A1 METHOD OF TREATING OR PREVENTING OSTEOPOROSIS COMPRISING ADMINISTERING TO A PATIENT IN NEED THEREOF AN EFFECTIVE AMOUNT OF PHARMACEUTICAL COMPOSITION COMPRISING BENZAMIDINE DERIVATIVES OR THEIR SALTS, AND ALENDRONIC ACID OR ITS SALT DONG WHA PHARM. CO., LTD. (KR) 2010-02-04 US claimed
EP-1773794-A4 AN IMPROVED PROCESS FOR PREPARING N-HYDROXY-4-[5- [4- (5-ISOPROPYL-2-METHYL-l, 3-THIAZOL-4-YL) -PHENOXY] -PENTOXY]-BENZAMIDINE DONG WHA PHARM IND CO LTD (KR) 2009-09-09 EP claimed
EP-1773794-A1 AN IMPROVED PROCESS FOR PREPARING N-HYDROXY-4-[5- [4- (5-ISOPROPYL-2-METHYL-l, 3-THIAZOL-4-YL) -PHENOXY] -PENTOXY]-BENZAMIDINE DONG WHA PHARMACEUTICAL INDUSTRIAL CO. LTD. (KR) 2007-04-18 EP claimed
WO-2006004368-A1 AN IMPROVED PROCESS FOR PREPARING N-HYDROXY-4-{5- [4- (5-ISOPROPYL-2-METHYL-l, 3-THIAZOL-4-YL) -PHENOXY] -PENTOXY }-BENZAMIDINE DONG WHA PHARMACEUTICAL. IND. CO., LTD. (KR) 2006-01-12 WO claimed
EP-1411935-A4 USE OF 4- (4-THIAZOLYL)PHENOXL] ALKOXY-BENZAMIDINE DERIVATIVES FOR TREATMENT OF OSTEOPOROSIS DONG WHA PHARM IND CO LTD (KR) 2005-11-09 EP claimed
US-20040186150-A1 Use of 4-[(4-thiazolyl)phenoxy]alkoxy-benzamidine derivatives for treatment of osteoporosis DONG WHA PHARMACEUTICAL CO., LTD. (KP) 2004-09-23 US claimed
EP-1411935-A1 USE OF 4- (4-THIAZOLYL)PHENOXL] ALKOXY-BENZAMIDINE DERIVATIVES FOR TREATMENT OF OSTEOPOROSIS DONG WHA PHARMACEUTICAL INDUSTRIAL CO. LTD. (KR) 2004-04-28 EP claimed
WO-2003007947-A1 USE OF 4-[(4-THIAZOLYL)PHENOXL] ALKOXY-BENZAMIDINE DERIVATIVES FOR TREATMENT OF OSTEOPOROSIS DONG WHA PHARM. IND. CO., LTD. (KR) 2003-01-30 WO claimed
CN-102149380-B A pharmaceutical composition for preventing or treating osteoporosis comprising benzamidine derivatives or their salts, and alendronic acid or its salt DONG WHA PHARM CO LTD 2012-12-05 CN disclosed
US-8242152-B2 Use of 4-[(4-thiazolyl)phenoxy]alkoxy-benzamidine derivatives for the prophylaxis and treatment of osteoporosis DONG WHA PHARMACEUTICAL CO., LTD. (KR) 2012-08-14 US disclosed
EP-1411935-A1 USE OF 4- (4-THIAZOLYL)PHENOXL] ALKOXY-BENZAMIDINE DERIVATIVES FOR TREATMENT OF OSTEOPOROSIS DONG WHA PHARMACEUTICAL INDUSTRIAL CO. LTD. (KR) 2004-04-28 EP disclosed
WO-2003007947-A1 USE OF 4-[(4-THIAZOLYL)PHENOXL] ALKOXY-BENZAMIDINE DERIVATIVES FOR TREATMENT OF OSTEOPOROSIS DONG WHA PHARM. IND. CO., LTD. (KR) 2003-01-30 WO disclosed
WO-2003007947-A1 USE OF 4-[(4-THIAZOLYL)PHENOXL] ALKOXY-BENZAMIDINE DERIVATIVES FOR TREATMENT OF OSTEOPOROSIS DONG WHA PHARM. IND. CO., LTD. (KR) 2003-01-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040186150-A1 Use of 4-[(4-thiazolyl)phenoxy]alkoxy-benzamidine derivatives for treatment of osteoporosis LTB4R, LTB4R2, CYSLTR1 PRMT1 1085/4885PLAU 1161/4885PLG 989/4885
US-20100120875-A1 USE OF 4-[(4-THIAZOLYL)PHENOXY]ALKOXY-BENZAMIDINE DERIVATIVES FOR TREATMENT OF OSTEOPOROSIS SOST, THPO, BMP4 PRMT1 1326/4885PLAU 670/4885PLG 701/4885
US-20100029595-A1 METHOD OF TREATING OR PREVENTING OSTEOPOROSIS COMPRISING ADMINISTERING TO A PATIENT IN NEED THEREOF AN EFFECTIVE AMOUNT OF PHARMACEUTICAL COMPOSITION COMPRISING BENZAMIDINE DERIVATIVES OR THEIR SALTS, AND ALENDRONIC ACID OR ITS SALT SOST, PTH1R, BPGM PRMT1 1416/4885PLAU 429/4885PLG 675/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.